<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885493</url>
  </required_header>
  <id_info>
    <org_study_id>5955</org_study_id>
    <nct_id>NCT02885493</nct_id>
  </id_info>
  <brief_title>Evaluation of Dysfunction of the Basal Ganglia Before a Parkinsonian Walking in the Elderly: Risk of Falling and Confusional State</brief_title>
  <acronym>EVAMARAGEX</acronym>
  <official_title>The Elderly 's Parkinsonian March : Risk Estimation Multiple Drops From an Evaluation Grid Covering the March, Executive Functions, Vision and Anxiety.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The strong relationship between falling and severity of cognitive impairment in the elderly
      is well established. The association premorbid gait and executive disorders suggests that
      they are under tension by the same mechanisms. The gait fortiori neurological are fall risk
      factors. Dysfunctions underlying disorders as Parkinson called march executive disorders are
      subcortical origin involving so the basal ganglia. This study is indeed based on the
      assumption that the dysfunction of the basal ganglia as observed in parkinsonian syndromes
      resulting in disorders of posture and walking, by dysexecutive syndrome, anxiety and the
      contrast vision disorders. These gait exposed to falls and dysexecutive these disorders with
      cognitive impairment and greater susceptibility to confusional states. The executive
      disorders, gait disorders, anxiety, disturbances of vision and especially saccadic eye
      movements, impaired vision contrasts are well established in the degenerative parkinsonian
      syndromes. This study proposes a new approach to assessing gait disorders to define a high
      risk of falling in the presence of parkinsonian walking in the elderly over 75 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>falls risks</measure>
    <time_frame>number of falls during follow-up of 24 months</time_frame>
    <description>Assess Falls development risk in the presence of parkinsonian walking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of confusional states</measure>
    <time_frame>follow-up of 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalizations</measure>
    <time_frame>follow-up of 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>follow-up of 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>the Elderly</condition>
  <arm_group>
    <arm_group_label>Falls is &lt;or = 1 year</arm_group_label>
    <description>Patients whose number of falls is &lt;or = 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>falls is&gt; 1 year</arm_group_label>
    <description>Patients whose numbers falls is&gt; 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>tests</intervention_name>
    <arm_group_label>Falls is &lt;or = 1 year</arm_group_label>
    <arm_group_label>falls is&gt; 1 year</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        the eldery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 75 years,

          -  man or woman,

          -  Diagnostic Criteria for Parkinson walking: at least 3 of the following symptoms:

          -  Loss of swinging arms,

          -  Decrease in stride walking slowly,

          -  feet as glued to the ground,

          -  Trample,

          -  piece U-turn,

          -  kyphotic Attitude,

          -  Tolerance screw physiotherapy screws

        Exclusion Criteria:

          -  Unrecovered delirium,

          -  Unable to walk for a distance of 6 meters in length without technical assistance,

          -  Traumatic fall phase of rehabilitation,

          -  Acute pathology,

          -  Unstabilized psychiatric pathology,

          -  Symptomatic orthostatic hypotension,

          -  Severe depressive syndrome untreated

          -  Subjects with a sufficient gap to explain the falls:

               -  cerebellar syndrome,

               -  a pyramidal syndrome with sequelae pyramidal deficit and cortical stroke

               -  peripheral pathology,

               -  rheumatic disease,

               -  orthopedic pathology,

          -  Mini Metam State Examination &lt;18,

          -  Parkinsonism induced by neuroleptics,

          -  Not cured cancer,

          -  Psychotropic drugs (benzodiazepines and antipsychotics) with significant sedative
             effect inducing excessive daytime sleepiness namely psychotropic half long life, and
             high dose over 2 psychotropic

          -  Severe heart failure

          -  Severe respiratory failure,

          -  Associated diseases and treatments interfering
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michèle KIESMANN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michèle KIESMANN, MD</last_name>
    <phone>03.88.11.55.52</phone>
    <email>Michele.Kiesmann@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy PERISSE, MD</last_name>
    <email>jeremie.perisse@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michèle KIESMANN, MD</last_name>
      <phone>03.88.11.55.52</phone>
      <email>Michele.Kiesmann@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Michèle KIESMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy PERISSE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges KALTENBACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas VOGEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine GALLO IMPERIALE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud SAUER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Céline FLEURY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson march</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

